Welcome to our dedicated page for Erasca SEC filings (Ticker: ERAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Erasca’s SEC filings overflow with clinical data tables, licensing minutiae, and risk factors tied to its mission of shutting down the RAS/MAPK pathway. Sorting through that detail to gauge cash runway or trial momentum can feel impossible. That’s why our platform starts with Erasca SEC filings explained simply, turning multi-hundred-page disclosures into concise briefs investors can use immediately.
Whether you need the full Erasca annual report 10-K simplified or prefer a quick glance at the latest Erasca quarterly earnings report 10-Q filing, Stock Titan delivers every document the moment it hits EDGAR. Our AI surfaces key metrics—phase progression, collaboration milestones, dilution risks—while real-time alerts flag Erasca Form 4 insider transactions real-time. Questions like “How are insiders trading before data read-outs?” are answered by dedicated feeds tracking Erasca insider trading Form 4 transactions and Erasca executive stock transactions Form 4.
Need context on sudden press releases? Drill into Erasca 8-K material events explained or dive into Erasca proxy statement executive compensation to see how option grants align with pipeline goals. For deeper diligence, our AI-powered dashboards provide Erasca earnings report filing analysis, cash-burn trends, and segment spending, so understanding Erasca SEC documents with AI becomes part of your daily workflow, not an after-hours chore.
Erasca (Nasdaq: ERAS) filed a Form 8-K disclosing the 24 June 2025 annual meeting results. 241.8 million of 283.3 million entitled shares were represented (≈85%).
- Director elections: Jonathan Lim 196.99 M for / 2.19 M withheld; James Bristol 178.36 M for / 20.81 M withheld; Valerie Harding-Start 177.00 M for / 22.17 M withheld. All three Class I directors were elected for terms expiring in 2028.
- Auditor ratification: KPMG LLP received 240.25 M for, 1.27 M withheld, 0.31 M against; 0 broker non-votes.
No additional proposals were presented, and the filing notes no changes to governance, strategy, or capital structure.
Erasca, Inc. (ERAS) – Form 4 insider filing: Director Michael David Varney received a grant of 120,000 non-qualified stock options on 06/24/2025 at an exercise price of $1.45 per share. The options are subject to a one-year cliff; 100% vest on 06/24/2026, contingent on his continued service, and expire on 06/23/2035. No shares were purchased or sold; the transaction code “A” denotes an award. Following the grant, Varney beneficially owns 120,000 derivative securities, held directly. The filing does not list any other equity transactions or changes in common-stock ownership.
The option award aligns the director’s incentives with shareholder value creation, but also adds up to 120,000 potential new shares to the company’s fully diluted count once exercised.
SEC Form 4 snapshot for Erasca, Inc. (ERAS)
On June 26 2025, Director Jean I. Liu reported the receipt of a new equity award under Erasca’s incentive plan. The filing discloses 120,000 stock options (right to buy common shares) granted on June 24 2025 at an exercise price of $1.45 per share. All of the options vest in a single tranche on June 24 2026, provided Ms. Liu remains in continuous service, and they expire on June 23 2035.
- No non-derivative share transactions were reported; the disclosure relates solely to the derivative option grant.
- Following the grant, Ms. Liu shows beneficial ownership of 120,000 options, held directly.
- The transaction is coded “A” (grant without payment) and was executed outside a Rule 10b5-1 trading plan.
Option awards are routine director compensation meant to align governance incentives with shareholder value creation. The long-dated expiration (10 years) and one-year cliff vesting structure encourage strategic, long-term decision-making. The filing does not indicate any open-market buying or selling, nor does it alter Erasca’s capital structure. From an investment perspective, the event is informational rather than financially material, but it does confirm continued board engagement and standard equity-based retention practices.
Erasca, Inc. (ERAS) – Form 4 insider filing
Director Julie Hambleton received an option grant for 120,000 shares of common stock on 24 June 2025 at an exercise price of $1.45 per share. The option was issued at no cost, vests 100 % on 24 June 2026, and expires on 23 June 2035. Following the grant, Hambleton beneficially owns 120,000 derivative securities, held directly. No non-derivative share transactions were reported. The filing represents routine equity compensation for a board member and does not indicate immediate open-market buying or selling activity.
Key points from Erasca, Inc. (ERAS) Form 4
On 06/24/2025 the company granted Director Valerie Denise Harding a stock option for 120,000 common shares at an exercise price of $1.45. The transaction is coded “A” (acquisition) and is held directly by the director. According to the footnote, 100% of the option vests on 06/24/2026, provided the director remains in continuous service, and the option expires on 06/23/2035. After the grant the reporting person holds 120,000 derivative securities; no non-derivative share ownership or sales were reported.
No Rule 10b5-1 trading plan or other special conditions were indicated, and there were no accompanying purchases, sales, or exercises. The filing represents routine director compensation with limited immediate impact on Erasca’s capital structure or cash flow.
Form 4 overview: On 06/24/2025, Erasca, Inc. (ticker ERAS) granted Director Pratik S. Multani a stock option to purchase 120,000 shares of common stock at an exercise price of $1.45 per share.
Key terms:
- Vesting: 100% of the option vests on 06/24/2026, contingent on continued service.
- Expiration: 06/23/2035, providing a 10-year exercise window after vesting.
- Ownership form: Direct.
No other acquisitions, dispositions, or non-derivative holdings were reported. The filing reflects a routine equity incentive intended to align the director’s interests with shareholders rather than an open-market purchase or sale. The disclosure contains no financial performance data or forward-looking statements.
On 06/24/2025, Erasca, Inc. (ERAS) director Alexander W. Casdin was granted 120,000 stock options to purchase common shares at an exercise price of $1.45. The award was disclosed in a Form 4 filed on 06/26/2025 and is classified as an acquisition rather than an open-market buy.
The options vest 100% on 06/24/2026, contingent on continued board service, and will expire on 06/23/2035. Casdin now holds 120,000 derivative securities, all directly owned. Because no underlying shares were bought or sold and the grant carries no immediate cash outlay, the filing reflects routine director compensation designed to align long-term incentives rather than a directional view on near-term share price.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
What is Erasca, Inc.'s primary focus?
What therapeutic candidates are central to Erasca's pipeline?
How does Erasca differentiate itself in the oncology market?
What role do collaborations and licensing agreements play for Erasca?
What is the significance of the RAS/MAPK pathway in Erasca’s treatment strategy?
How is Erasca approaching its clinical development?
What type of company is Erasca?
How does Erasca ensure the quality of its research initiatives?
